TABLE 3.

Screening raw results for unexpected beneficial effects and repurposing opportunities under the no pooling model

Outcome	Thiazide	ARB	CCB	Beta Blocker	ACE	RR (p)
Acute myocardial infarction*	0.4 (0.2,0.6)	0.8 (0.4,1.2)	1.1 (0.6,1.5)	1.1 (0.7,1.4)	0.9 (0.7,1.1)	0.52 (p = 0.96)
Pulmonary heart disease*	1.2 (0.5,1.9)	0.4 (0.2,0.7)	1.3 (0.9,1.8)	1.2 (0.8,1.5)	0.9 (0.6,1.1)	0.52 (p = 0.97)
Aneurysms	0.5 (0.2,0.8)	1.0 (0.6,1.5)	1.0 (0.6,1.4)	1.1 (0.7,1.4)	0.9 (0.6,1.2)	0.55 (p = 0.94)
Varicose Veins*,**	1.6 (1.1,2.2)	1.3 (0.8,1.9)	1.1 (0.7,1.5)	1.3 (0.9,1.6)	0.7 (0.5,0.9)	0.65 (p = 0.93)
Regional enteritis, ulcerative colitis	0.9 (0.4,1.3)	0.4 (0.1,0.7)	0.8 (0.4,1.2)	1.2 (0.8,1.6)	0.8 (0.6,1.0)	0.55 (p = 0.91)
Schizophrenia, psychosis*	0.8 (0.4,1.3)	0.3 (0.1,0.7)	1.1 (0.4,1.2)	1.4 (0.8,1.6)	0.7 (0.6,1.0)	0.55 (p = 0.94)
Gastrointestinal hemorrhage	3.0 (2.2,3.7)	2.0 (1.4,2.5)	3.3 (2.4,4.1)	2.9 (2.3,3.6)	2.6 (2.2,3.1)	0.77 (p = 0.92)
Paralysis*,**	0.7 (0.3,1.1)	0.2 (0.1,0.4)	0.8 (0.4,1.1)	0.7 (0.4,1.0)	0.6 (0.4,0.8)	0.38 (p = 0.97)
Symptoms of mental and substance use conditions	1.6 (0.9,2.4)	1.6 (1.0,2.1)	1.4 (0.9,1.9)	1.4 (1.0,1.8)	0.9 (0.7,1.1)	0.66 (p = 0.92)

Note: Numbers are percents. RR is risk ratio of lowest to second lowest rate. p is pseudo‐posterior probability that the lowest estimated rate is truly the lowest. The bold faced value in each row corresponds to the drug (column) estimated to have a protective effect for the condition corresponding to that row.

^*Under the single outcome pooling model.

^**Under the all outcome pooling model.